Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review
C Ay, M Napolitano, A Hassoun, R Tomic… - …, 2024 - Wiley Online Library
Introduction Consensus over the definition of recombinant factor VIII (rFVIII) product
classification in haemophilia A is lacking. rFVIII products are often classified as standard half …
classification in haemophilia A is lacking. rFVIII products are often classified as standard half …
[HTML][HTML] Monitoring coagulation factors during surgery. A systematic review
JE Megías-Vericat, S Bonanad-Boix… - Farmacia …, 2021 - Elsevier
Objective The management of surgeries in patients with hemophilia is complex and requires
adequate clotting factor adjustment to avoid bleeding complications and excessive factor …
adequate clotting factor adjustment to avoid bleeding complications and excessive factor …
Pharmacokinetic‐guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A
K Huang, Y Zhen, G Li, X Wu, Z Chen, R Wu - Haemophilia, 2021 - Wiley Online Library
Background The traditional weight‐based dosing regimen can lead to under‐or overdosage
due to the interindividual variability of pharmacokinetic (PK) parameters. PK‐guided …
due to the interindividual variability of pharmacokinetic (PK) parameters. PK‐guided …
[HTML][HTML] Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
K Huang, Y Zhen, G Li, X Wu, Z Chen, R Wu - Research and Practice in …, 2022 - Elsevier
Abstract Background BAY81‐8973 (Kovaltry; Bayer, Berkeley, CA, USA) was reported with
enhanced pharmacokinetic (PK) profiles compared with some other standard half‐life (SHL) …
enhanced pharmacokinetic (PK) profiles compared with some other standard half‐life (SHL) …
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A …
K Huang - Advances in Therapy, 2024 - Springer
With great interest, I carefully read the paper by Gu et al., which aimed to compare the cost-
effectiveness between standard prophylaxis and pharmacokinetic(PK)-guided prophylaxis …
effectiveness between standard prophylaxis and pharmacokinetic(PK)-guided prophylaxis …
A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B
SF Koopman, TMHJ Goedhart… - British journal of …, 2024 - Wiley Online Library
Abstract Aims Recombinant factor IX Fc fusion protein (rFIX‐Fc) is an extended half‐life
factor concentrate administered to haemophilia B patients. So far, a population …
factor concentrate administered to haemophilia B patients. So far, a population …
BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
C Santoro, B Fuh, PQ Le, P Maes… - European journal of …, 2020 - Wiley Online Library
Objectives To report interim data from TAURUS, a study assessing real‐world prophylactic
treatment with unmodified, full‐length recombinant FVIII BAY 81‐8973 (Kovaltry®; Bayer) …
treatment with unmodified, full‐length recombinant FVIII BAY 81‐8973 (Kovaltry®; Bayer) …
[HTML][HTML] Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with …
A Solms, S Lalezari, A Shah, G Kenet - Haemophilia, 2020 - ncbi.nlm.nih.gov
BAY 81-8973 (Kovaltry, Bayer, Berkeley, CA, USA) is an unmodified, full-length,
recombinant factor VIII (rFVIII). It has the same primary amino-acid sequence as sucrose …
recombinant factor VIII (rFVIII). It has the same primary amino-acid sequence as sucrose …
Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A
K Huang, Y Wang, Y Zhen, G Li, X Wu, N Zhang… - Thrombosis …, 2022 - Elsevier
Introduction As the most commonly used FVIII concentrate in China, the individualized
pharmacokinetics (PK) and clinical outcomes of Kovaltry (BAY81-8973) are not fully …
pharmacokinetics (PK) and clinical outcomes of Kovaltry (BAY81-8973) are not fully …
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) …
R Chen, D Gultyaev, J Lister, R Han, N Hu… - BMC Medical Research …, 2022 - Springer
Background Long-term prophylactic therapy is considered the standard of care for
hemophilia A patients. This study models the long-term clinical and cost outcomes of two …
hemophilia A patients. This study models the long-term clinical and cost outcomes of two …